Results 51 to 60 of about 36,764 (181)

Biosynthesis of (S)-HMG-CoA and purification and characterization of HMG-CoA reductase from the archaeon Haloferax volcanii

, 1995
Two methods have been developed for use in the continuing investigation of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. A method which employs Pseudomonas mevalonii HMG-CoA reductase for the enzymic synthesis of (S)-HMG-CoA, the physiologic
Bischoff, Kenneth Mark
core  

Characterization of an HMG-CoA reductase from Listeria monocytogenes that exhibits dual coenzyme specificity

, 2006
HMG-CoA reductase (HMGR) is an enzyme critical for cellular cholesterol synthesis in mammals and isoprenoid synthesis in certain eubacteria, catalyzing the NAD(P)H-dependent reduction of HMG-CoA to mevalonate.
Tabernero, Lydia; id_orcid, Theivagt, Amy E., Beresford, Nicola J., Friesen, Jon A., Amanti, Elise N.   +4 more
core   +1 more source

Metabolome analysis identified exogenous cholesterol within lipid rafts that activate the Akt/mTOR signaling pathway in epithelial ovarian cancer

International Journal of Cancer, Volume 159, Issue 1, Page 257-268, 1 July 2026.
What's New? Epithelial ovarian cancer (EOC) is a severe malignancy with few effective treatment options. While the mechanisms remain unclear, changes in lipid metabolism may fuel tumor growth and EOC progression, offering a possible path for new treatments.
Hitomi Sakaguchi‐Mukaida, Kosuke Hiramatsu, Tatsuo Masuda, Mamoru Kakuda, Satoshi Nakagawa, Tadashi Iwamiya, Shinya Matsuzaki, Tetsuji Naka, Yutaka Ueda, Tadashi Kimura, Michiko Kodama   +10 more
wiley   +1 more source

Genomic and Sex Contributions to Interindividual Variability in Pitavastatin Bioavailability

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 1, July 2026.
ABSTRACT Aim This study investigates pharmacogenetic determinants of pitavastatin disposition using a candidate‐gene approach. Methods In 48 healthy volunteers, 138 variants across 40 genes involved in drug metabolism and transport were analysed to assess their relationship with pitavastatin pharmacokinetics, alongside the influence of sex and ...
Eva González‐Iglesias, Sofía Moreno‐Pérez de Villar, Dolores Ochoa, Manuel Román, Jesús Novalbos, Samuel Martín‐Vilchez, Alejandro de Miguel, Francisco Abad‐Santos   +7 more
wiley   +1 more source

Increase in serum and bile cholesterol and HMG-CoA reductase by lovastatin in rats

, 1991
Lovastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, is effective in the treatment of hypercholesterolemic patients and is currently being evaluated as a potential agent for dissolving gallstones.
D. H. Beach, S. Yamauchi, W. G. Linscheer   +2 more
core   +1 more source

Drugs that act on both G protein‐coupled receptors (GPCRs) and kinases: potentiation of effects, side effects and general aspects of drug pleiotropy

British Journal of Pharmacology, Volume 183, Issue 13, Page 3471-3483, July 2026.
Abstract Background A drug designed for a specific target often interacts with multiple targets, either unintentionally or as part of its intended mechanism of action. This has been called pharmacological pleiotropy or polypharmacology. There are key endogenous ligands such as ATP, GABA and glutamate that act on various proteins in humans. Furthermore,
Hampus Ljunggren, Aleksandr Sokolov, Flavio Ballante, Robert Fredriksson, Francisco Lagunas‐Rangel, Alexander S. Hauser, Stefan Knapp, Jörgen Jonsson, Helgi B. Schiöth   +8 more
wiley   +1 more source

Unveiling a New Link: Cholesterol Deficiency in Smith–Lemli–Opitz and Niemann–Pick C as a Driver of Ciliopathies

American Journal of Medical Genetics Part A, Volume 200, Issue 6, Page 1179-1191, June 2026.
ABSTRACT The ciliopathies are a group of genetic disorders caused by defective function of either the primary cilia (a large number) or the motile cilia (a much smaller number). These have been defined as diseases with mutations in genes encoding individual ciliary or cilia‐associated proteins.
Robert P. Erickson, Maria Teresa Fiorenza   +1 more
wiley   +1 more source

Effect of Atorvastatin Combined With Herb‐Partitioned Moxibustion on PON‐1 in Patients With Atherosclerotic Cerebral Infarction: A Randomized Controlled Trial

Brain and Behavior, Volume 16, Issue 6, June 2026.
Atorvastatin combined with herb‐partitioned moxibustion significantly improved oxidative stress markers, blood rheology, vascular physiological function, and overall clinical efficacy in patients with atherosclerotic cerebral infarction while maintaining a favorable safety profile.
Wei An, Xinlei Hou, Ning Wei, Yuzhuo Zhou, Xinsheng Xie, Ze Jin, Linjing Wang, Xuzhou Li, Weijia Zhuang, Di Chen   +9 more
wiley   +1 more source

Do statins offer therapeutic potential in inflammatory arthritis? [PDF]

, 2004
No abstract ...
McInnes, I.B., McCarey, D., Sattar, N.
core   +1 more source

Diagnostic and Therapeutic Challenges in Statin‐Induced Necrotizing Autoimmune Myopathy in an Elderly Patient: A Rare Case Report

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT We present the case of a 78‐year‐old woman with metabolic syndrome and a history of multiple ischemic strokes who developed progressive symmetrical proximal muscle weakness, predominantly affecting the lower extremities, while on atorvastatin.
Nischal Shrestha, Abdirahman Hassan, Jennifer Ann Evans   +2 more
wiley   +1 more source